IVDR Survival Guide: Know the 4 Main Challenges and How to Overcome Them

Presented by

Premier Research - Matt Nowland, VP, Regulatory Affairs & Quality and Caroline Perez, Associate Director, Regulatory Affairs

About this talk

With the positive aim of increasing patient safety, the In Vitro Diagnostic Regulation (IVDR) has fundamentally changed the way in vitro diagnostics (IVD) are regulated in the EU. The depth of expectations for review and documentation have increased substantially. As a result, IVD sponsors are having to adapt to a daunting set of regulatory updates. This webinar walks through the four primary challenges to IVDR conversion and provides solutions to simplify and de-stress the process so that IVD manufacturers can approach deadlines with more confidence and avoid having products pulled from the market. Topics addressed: New IVDR product classification system Under the new IVDR, a four-class system replaces the old in vitro diagnostic medical devices directive (IVDD) two-class system. Significantly more products fall into the higher risk groups. What are the most notable new rules and modifications to existing rules? How open are they to interpretation? How do you determine what you need to do differently for compliance now? Dramatic increase in Notified Body (NB) oversight It’s estimated that, under the new system, the proportion of products requiring NB oversight will increase from 20% to 80-90%. How will this affect the level of scrutiny on products old and new, the conformity assessment criteria and the level of documentation required? Combined pressures creating a NB bottleneck Just as demand is up, the number of NBs has diminished. Excessive demand, the Consolidated NB initiative, increased training requirements and COVID-19 have created a perfect storm making NB evaluations a rare commodity. What do you do when you need one, but the wait time exceeds your product registration date? Clinical evidence and performance requirements Whereas in the past, clinical evidence was not needed, IVD manufacturers now need to show a legitimate level of product performance. But what is acceptable evidence and what isn’t for the different classes of devices?
Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (96)
Subscribers (4570)
Premier Research is a clinical research company, dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.